https://orcid.org/0000-0001-6700-3001
References
- Minchiotti L, Galliano M, Caridi G, et al. Congenital analbuminaemia: molecular defects and biochemical and clinical aspects. Biochim Biophys Acta. 2013;1830:5494–5550.
- Minchiotti L, Caridi G, Campagnoli M, et al. Diagnosis, phenotype, and molecular genetics of congenital analbuminemia. Front Genet. 2019;10:336.
- Suppressa P, Carbonara C, Lugani F, et al. Congenital analbuminemia in a patient affected by hypercholesterolemia: a case report. World J Clin Cases. 2019;26:466–472.
- D’Addato S, Fogacci F, Cicero AFG, et al. Severe hypercholesterolaemia in a paediatric patient with congenital analbuminaemia. Nutr Metab Cardiovasc Dis. 2019;29:316–317.
- Watkins S, Madison J, Galliano M, et al. A nucleotide insertion and frameshift cause analbuminemia in an Italian family. Proc Natl Acad Sci USA. 1994;91:2275–2279.
- Toye JM, Lemire EG, Baerg KL. Perinatal and childhood morbidity and mortality in congenital analbuminemia. Paediatr Child Health. 2012;17:20–23.
- Staps P, Hogeveen M, Fuijkschot J, et al. Understanding fetal factors that contribute to preterm birth: Sjögren-Larsson syndrome as a model. J Perinat Med. 2018;46:523–529.
- Lyon AW, Meinert P, Bruce GA, et al. Influence of methodology on the detection and diagnosis of congenital analbuminemia. Clin Chem. 1998;44:2365–2367.
- DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41:1247–1266.
- Mannens G, Meuldermans W, Snoeck E, et al. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl). 1994;114:566–572.
- Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Clin Pharmacokinet. 1999;37:177–193.
- Minghetti PP, Ruffner DE, Kuang WJ, et al. Molecular structure of the human albumin gene is revealed by nucleotide sequence within q11-22 of chromosome 4. J Biol Chem. 1986;261:6747–6757.
- Minchiotti L, Galliano M, Iadarola P, et al. The molecular defect in a COOH- terminal-modified and shortened mutant of human serum albumin. J Biol Chem. 1989;264:3385–3389.
- Nilsen J, Trabjerg E, Grevys A, et al. An intact C-terminal end of albumin is required for its long half-life in humans. Commun Biol. 2020;3:181.
- Ruhoff MS, Greene MW, Peters T Jr. Location of the mutation site in the first two reported cases of analbuminemia. Clin Biochem. 2010;43:525–527.
- Campagnoli M, Hansson P, Dolcini L, et al. Analbuminemia in a Swedish male is caused by the Kayseri mutation (c228_229delAT). Clin Chim Acta. 2008;396:89–92.